Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

PTC Therapeutics Inc. buy klostergang

Start price
€18.93
05.09.17 / 50%
Target price
€25.26
06.11.17
Performance (%)
-16.91%
End price
€15.73
06.11.17
Summary
This prediction ended on 06.11.17 with a price of €15.73. The prediction for PTC Therapeutics Inc. disappointed with a performance of -16.91%. klostergang has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
PTC Therapeutics Inc. -15.000% -15.000% -26.882% -24.022%
iShares Core DAX® 1.133% -0.156% 14.356% 15.491%
iShares Nasdaq 100 0.815% 8.801% 34.123% 51.862%
iShares Nikkei 225® 1.990% 3.286% 10.759% 7.673%
iShares S&P 500 -0.014% 5.438% 26.681% 44.772%

Comments by klostergang for this prediction

In the thread PTC Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -16.91%
Target price 25.256
Change
Ends at 06.11.17

TC Therapeutics with NDA on 28.09.2017

PTC Therapeutics Inc.’s (PTCT) New Drug Application for Translarna, a treatment for nonsense mutation Duchenne muscular dystrophy, is all set to be reviewed by an FDA panel on September 28, 2017.

The FDA’s final decision on Translarna will be known by October 24, 2017.

Translarna is approved within the European Union (EU) Member States, Iceland, Liechtenstein, Norway, Israel and South Korea.

Ever since its launch in December 2014, Translarna has had substantial year-over-year net sales growth.

Sales of Translarna, which were $34 million in 2015, more than doubled to $81 million in 2016. Looking ahead to full-year 2017, the Company expects Translarna to bring home sales in the range of $115 million to $130 million.

The first FDA-approved treatment for DMD is Exondys 51, manufactured by Sarepta Therapeutics Inc. (SRPT). Exondys 51, specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, was approved in the U.S. last September.

The second approved drug for DMD is Emflaza, developed by privately held Marathon Pharmaceuticals. Emflaza is also the first drug in the United States approved for use by patients who are 5 years or older with DMD, regardless of genetic mutation.

TC Therapeutics purchased all rights to Emflaza in April of this year.

Prediction Buy
Perf. (%) -16.91%
Target price 25.256
Change
Ends at 06.11.17

(Laufzeit überschritten)